Welcome to this week's Gastroenterology and Endoscopy News Roundup, where we bring you the most important updates and research findings for gastroenterology professionals. This episode covers five critical stories from the week of October 21-28, 2025, including new clinical guidelines, groundbreaking research on procedure safety, and the latest technological innovations in endoscopy.

1. AGA Releases Updated Barrett's Esophagus Surveillance Guideline

The American Gastroenterological Association has published a significant update to its clinical practice guideline on Barrett's esophagus surveillance. The new guideline represents a paradigm shift from uniform monitoring to a risk-based, individualized approach.

Clinical Impact: This guideline helps optimize resource allocation while improving early detection of neoplasia in higher-risk patients.

2. OCULUS Trial: Holding GLP-1 Agonists Before Endoscopy Reduces Risk

The OCULUS randomized controlled trial, presented at ACG 2025, provides the first RCT evidence on managing GLP-1/GIP-1 receptor agonists before upper endoscopy.

Clinical Impact: Strong evidence for holding these increasingly common medications before elective upper endoscopy to ensure patient safety and reduce aspiration risk.

3. Landmark Study Reveals 22% of Esophageal Cancers Missed on Endoscopy

A large population-based study from Finland and Sweden analyzed over 15,000 Barrett's esophagus patients and uncovered concerning rates of post-endoscopy esophagogastric cancers (PEEC).

Clinical Impact: Highlights urgent need for quality metrics in upper endoscopy, similar to adenoma detection rates in colonoscopy, to reduce missed cancers.

4. Fujifilm Launches ELUXEO 8000 Endoscopic Imaging System

FUJIFILM Healthcare Americas has unveiled its next-generation endoscopy platform with enhanced imaging capabilities.

Clinical Impact: Backward compatibility offers practical upgrade path for existing users while enhancing diagnostic and therapeutic capabilities.

5. FDA Approves Once-Monthly Omvoh Injection for Ulcerative Colitis

The FDA has approved a more convenient maintenance regimen for Eli Lilly's mirikizumab-mrkz (Omvoh) for moderately to severely active ulcerative colitis.

Clinical Impact: Simplified treatment regimen may improve patient adherence and reduce injection burden.

Sponsor

This episode is sponsored by DigestiveJobs.com

DigestiveJobs.com is the leading career resource for gastroenterology and endoscopy professionals. Whether you're seeking new opportunities, looking to hire talented clinicians, or exploring career advancement, DigestiveJobs.com connects you with the best positions and candidates in the field.

Visit DigestiveJobs.com to explore current opportunities and advance your career in gastroenterology.

https://www.gastroendopod.com

In this episode, we cover five crucial updates shaping gastroenterology and endoscopy practice in 2025. From the practice-changing ENDURO trial comparing endoscopic to surgical approaches for malignant gastric outlet obstruction, to the latest EASL hepatitis B management guidelines, AI applications in endoscopy, sedation innovations, and biomarker-driven approaches to IBS.

Resources & Links

ENDURO Trial & EUS-Guided Gastroenterostomy

• ENDURO Study Protocol - Trials Journal
• ENDURO Trial Results - The Lancet Gastroenterology & Hepatology
• EUS-GE Overview - Gastroenterology & Endoscopy News
• Prospective Study - Gastrointestinal Endoscopy

EASL 2025 Hepatitis B Guidelines

• EASL HBV Guidelines 2025 - Journal of Hepatology
• EASL Guidelines Summary - EASL Website
• HBV Guidelines PDF - Hepatitis B Foundation

AI in Endoscopy

• AI and Polyp Detection Review - PMC
• AI-Assisted Colonoscopy Meta-Analysis - Annals of Internal Medicine
• Use of AI in Colonoscopy - Gastrointestinal Endoscopy
• Endoscopist Deskilling Study - The Lancet
• Bibliometric Analysis - Frontiers in Medicine

Sedation Innovations

• Remimazolam Review - Clinical Endoscopy
• Remimazolam vs Propofol Meta-Analysis - British Journal of Anaesthesia
• Remimazolam Comprehensive Review - World Journal of GI Endoscopy
• Remimazolam Real-World Study - BMC Gastroenterology
• Safety and Efficacy Comparison - BMC Anesthesiology

IBS Biomarkers & Microbiome

• 2025 Seoul Consensus on IBS - PMC
• 16S rRNA Microbiome Biomarkers for IBS - PMC
• International Consensus on Microbiome Testing - Gut Microbiota for Health
• Gut Microbiome Resilience Review - Frontiers in Microbiology

This podcast is for educational purposes only and does not constitute medical advice. Always consult current guidelines and use clinical judgment when making treatment decisions.

https://www.gastroendopod.com

In this quick-hit episode, we cover the freshest guidelines reshaping IBD, colorectal surveillance, gastric premalignancy, and gastroparesis management. Dive into cutting-edge research on AI for efficiency, targeted therapies, H. pylori strategies, advanced endoscopy, and cost-saving insights. Plus, spotlight on new tech warnings, bariatric devices, GERD diagnostics, and the game-changing FDA approval for subcutaneous Tremfya in UC. Perfect for busy GI pros—actionable takeaways to level up your practice.

Key Segments and Highlights:

1. Guidelines Rundown:
   • BSG on IBD: Enhanced primary care pathways, CRC risk stratification, and patient adherence strategies to reduce post-colonoscopy cancers.
   • ACG on Gastric Premalignancy: First-ever guidance on atrophic gastritis, GIM, dysplasia—focus on H. pylori eradication and tailored surveillance.
   • BSG on Colorectal Surveillance: Clear start/stop criteria post-polypectomy and in IBD, with tips for better patient buy-in.
   • AGA on Gastroparesis: 12 recs for diagnosis (scintigraphy) and treatments (prokinetics, G-POEM)—emphasizing personalized, multidisciplinary care.
   • Rome/International on Gastroparesis: Aligns with AGA, adds psychosocial screening and global non-pharma standards. Takeaway: Download from AGA/ACG/BSG sites and audit your protocols.
2. Research Pulse:
   • AI in Guideline Development (AGA Pilot): Cuts review time/costs dramatically for Crohn's biologics—use with human validation.
   • Targeted Drug Delivery: Nanoparticles for IBD/motility; watch for retention improvements.
   • H. pylori in MI Patients (ESC Data): Selective screening for high-risk antiplatelet users to curb GI bleeds.
   • EUS-Guided Gastroenterostomy: Standardization boosts success >90%; includes troubleshooting videos.
   • ASIDE Gastroenterology New Issue: Covers MMF in IBD, tofacitinib in peds UC, ESD aids, gastric cancer immunotherapy, and more.
   • Optical Enhancement Endoscopy RCT: 92% sensitivity for gastric metaplasia/neoplasia—upgrade for high-risk screens.
   • Hospital Affiliation Costs Study: Independents save 20-30% without quality loss; implications for value-based care. Takeaway: Subscribe to journals and experiment with AI cautiously.
3. Devices, Tech, and Approvals:
   • Medical AI Warnings: Address biases in GI datasets; great for polyps, risky for diverse monitoring.
   • ESGE on Bariatric Endoscopy: Devices like balloons and duodenal resurfacing—10-15% weight loss, low AEs; await long-term RCTs.
   • New GERD Tools: AFS (EGJ integrity), Milan (manometry), pHoenix (AET), COuGH RefluX (symptoms), Lyon (integrated phenotyping)—revolutionize grading.
   • FDA Approval: SubQ Tremfya for UC: 50% endoscopic response at Week 12; convenient induction sans IV. Takeaway: Train on AI pitfalls and adopt one GERD tool quarterly.

Themes & Standouts: Personalization dominates, AI as a tool (not takeover), tech for precision. Revamp gastroparesis care, smart H. pylori screens, and embrace subQ Tremfya.

Resources: Links to guidelines, studies, and journals in the episode description. Submit Q&A via app/email. Next up: UEG Week previews!

Sponsored by digestivejobs.com

https://www.gastroendopod.com